Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

被引:0
|
作者
José Trigo
Mónica García-Cosío
Almudena García-Castaño
Montserrat Gomà
Ricard Mesia-Nin
Elena Ruiz-Bravo
Ainara Soria-Rivas
Paola Castillo
Irene Braña-García
Margarita Alberola-Ferranti
机构
[1] HC Marbella International Hospital,
[2] Spanish Society of Medical Oncology (SEOM),undefined
[3] Ramón y Cajal University Hospital,undefined
[4] Spanish Society of Pathological Anatomy (SEAP),undefined
[5] Marqués de Valdecilla University Hospital,undefined
[6] Spanish Society of Medical Oncology (SEOM),undefined
[7] Bellvitge University Hospital,undefined
[8] Spanish Society of Pathological Anatomy (SEAP),undefined
[9] Catalan Institute of Oncology (ICO),undefined
[10] Badalona Applied Research Group in Oncology,undefined
[11] Germans Trias i Pujol Research Institute,undefined
[12] Spanish Society of Medical Oncology (SEOM),undefined
[13] La Paz University Hospital,undefined
[14] Spanish Society of Pathological Anatomy (SEAP),undefined
[15] Ramón y Cajal University Hospital,undefined
[16] Spanish Society of Medical Oncology (SEOM),undefined
[17] Clínic de Barcelona Hospital,undefined
[18] Spanish Society of Pathological Anatomy (SEAP),undefined
[19] Vall d’Hebron University Hospital,undefined
[20] Spanish Society of Medical Oncology (SEOM),undefined
[21] Vall d’Hebron University Hospital,undefined
[22] Spanish Society of Pathological Anatomy (SEAP),undefined
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
PD-L1; Prognosis; Individualized therapy; Response to treatment; Epstein Barr virus; Human papillomavirus;
D O I
暂无
中图分类号
学科分类号
摘要
The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
引用
收藏
页码:1890 / 1902
页数:12
相关论文
共 50 条
  • [31] Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    Garcia-Carbonero, R.
    Vilardell, F.
    Jimenez-Fonseca, P.
    Gonzalez-Campora, R.
    Gonzalez, E.
    Cuatrecasas, M.
    Capdevila, J.
    Aranda, I.
    Barriuso, J.
    Matias-Guiu, X.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (03): : 243 - 256
  • [32] Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    Garcia-Alfonso, P.
    Garcia-Foncillas, J.
    Salazar, R.
    Perez-Segura, P.
    Garcia-Carbonero, R.
    Musulen-Palet, E.
    Cuatrecasas, M.
    Landolfi, S.
    Ramon y Cajal, S.
    Navarro, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (04): : 264 - 273
  • [33] Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    P. García-Alfonso
    J. García-Foncillas
    R. Salazar
    P. Pérez-Segura
    R. García-Carbonero
    E. Musulén-Palet
    M. Cuatrecasas
    S. Landolfi
    S. Ramón y Cajal
    S. Navarro
    Clinical and Translational Oncology, 2015, 17 : 264 - 273
  • [34] Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    R. García-Carbonero
    F. Vilardell
    P. Jiménez-Fonseca
    R. González-Campora
    E. González
    M. Cuatrecasas
    J. Capdevila
    I. Aranda
    J. Barriuso
    X. Matías-Guiu
    Clinical and Translational Oncology, 2014, 16 : 243 - 256
  • [35] Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
    de Castro, J.
    Cobo, M.
    Isla, D.
    Puente, J.
    Reguart, N.
    Cabeza, B.
    Gayete, A.
    Sanchez, M.
    Torres, M. I.
    Ferreiros, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 11 - 23
  • [36] Recommendations forradiological diagnosis and assessment of treatment response in lung cancer: A national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
    Ferreiros, J.
    Cabeza, B.
    Gayete, A.
    Sanchez, M.
    Torres, M. I.
    Cobo, M.
    Isla, D.
    Puente, J.
    Reguart, N.
    de Castro, J.
    RADIOLOGIA, 2015, 57 (01): : 66 - 78
  • [37] Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
    J. de Castro
    M. Cobo
    D. Isla
    J. Puente
    N. Reguart
    B. Cabeza
    A. Gayete
    M. Sánchez
    M. I. Torres
    J. Ferreirós
    Clinical and Translational Oncology, 2015, 17 : 11 - 23
  • [38] Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
    Joan Albanell
    Xavier Andreu
    María José Calasanz
    Ángel Concha
    José María Corominas
    Tomás García-Caballero
    José Antonio López
    Fernando López-Ríos
    Santiago Ramón y Cajal
    Francisco J. Vera-Sempere
    Ramón Colomer
    Miguel Martín
    Emilio Alba
    Antonio González-Martín
    Antonio Llombart
    Ana Lluch
    José Palacios
    Clinical and Translational Oncology, 2009, 11 : 363 - 375
  • [39] Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    Felip, E.
    Concha, A.
    de Castro, J.
    Gomez-Roman, J.
    Garrido, P.
    Ramirez, J.
    Isla, D.
    Sanz, J.
    Paz-Ares, L.
    Lopez-Rios, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 103 - 112
  • [40] Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    E. Felip
    Á. Concha
    J. de Castro
    J. Gómez-Román
    P. Garrido
    J. Ramírez
    D. Isla
    J. Sanz
    L. Paz-Ares
    F. López-Ríos
    Clinical and Translational Oncology, 2015, 17 : 103 - 112